Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, cla...
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
About this item
Full title
Author / Creator
Australasian Leukaemia and Lymphoma Group , Swiss Group for Clinical Cancer Research , German Hodgkin Study Group , Arbeitsgemeinschaft Medikamentöse Tumortherapie , Nordic Lymphoma Group , Borchmann, Peter , Ferdinandus, Justin , Schneider, Gundolf , Moccia, Alden , Greil, Richard , Hertzberg, Mark , Schaub, Valdete , Hüttmann, Andreas , Keil, Felix , Dierlamm, Judith , Hänel, Mathias , Novak, Urban , Meissner, Julia , Zimmermann, Andreas , Mathas, Stephan , Zijlstra, Josée M , Fosså, Alexander , Viardot, Andreas , Hertenstein, Bernd , Martin, Sonja , Giri, Pratyush , Scholl, Sebastian , Topp, Max S , Jung, Wolfram , Vucinic, Vladan , Beck, Hans-Joachim , Kerkhoff, Andrea , Unger, Benjamin , Rank, Andreas , Schroers, Roland , zum Büschenfelde, Christian Meyer , de Wit, Maike , Trautmann-Grill, Karolin , Kamper, Peter , Molin, Daniel , Kreissl, Stefanie , Kaul, Helen , von Tresckow, Bastian , Borchmann, Sven , Behringer, Karolin , Fuchs, Michael , Rosenwald, Andreas , Klapper, Wolfram , Eich, Hans-Theodor , Baues, Christian , Zomas, Athanasios , Hallek, Michael , Dietlein, Markus , Kobe, Carsten and Diehl, Volker
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Intensified systemic chemotherapy has the highest primary cure rate for advanced-stage, classical Hodgkin lymphoma but this comes with a cost of severe and potentially life long, persisting toxicities. With the new regimen of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD), we aimed to improve...
Alternative Titles
Full title
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
Authors, Artists and Contributors
Author / Creator
Swiss Group for Clinical Cancer Research
German Hodgkin Study Group
Arbeitsgemeinschaft Medikamentöse Tumortherapie
Nordic Lymphoma Group
Borchmann, Peter
Ferdinandus, Justin
Schneider, Gundolf
Moccia, Alden
Greil, Richard
Hertzberg, Mark
Schaub, Valdete
Hüttmann, Andreas
Keil, Felix
Dierlamm, Judith
Hänel, Mathias
Novak, Urban
Meissner, Julia
Zimmermann, Andreas
Mathas, Stephan
Zijlstra, Josée M
Fosså, Alexander
Viardot, Andreas
Hertenstein, Bernd
Martin, Sonja
Giri, Pratyush
Scholl, Sebastian
Topp, Max S
Jung, Wolfram
Vucinic, Vladan
Beck, Hans-Joachim
Kerkhoff, Andrea
Unger, Benjamin
Rank, Andreas
Schroers, Roland
zum Büschenfelde, Christian Meyer
de Wit, Maike
Trautmann-Grill, Karolin
Kamper, Peter
Molin, Daniel
Kreissl, Stefanie
Kaul, Helen
von Tresckow, Bastian
Borchmann, Sven
Behringer, Karolin
Fuchs, Michael
Rosenwald, Andreas
Klapper, Wolfram
Eich, Hans-Theodor
Baues, Christian
Zomas, Athanasios
Hallek, Michael
Dietlein, Markus
Kobe, Carsten
Diehl, Volker
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_DiVA_org_uu_539662
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_539662
Other Identifiers
ISSN
0140-6736,1474-547X
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(24)01315-1
